{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:51:57Z","timestamp":1790268717380,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,3,15]],"date-time":"2020-03-15T00:00:00Z","timestamp":1584230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Direct\u2010acting antiviral therapy for hepatitis C virus (HCV) is effective, but few prospective studies among people with ongoing injecting drug use exist. This study evaluated the efficacy of elbasvir\/grazoprevir in people with HCV genotype 1\/4 (G1\/4) infection and recent injecting drug use. An exploratory aim evaluated the feasibility of fingerstick point\u2010of\u2010care HCV RNA testing prior to and following treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>DARLO\u2010C (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: NCT02940691) is an open\u2010label phase 4 trial. Participants were recruited between May 2017 and March 2018 from two drug treatment clinics, two hospital clinics, and one community clinic in Australia. Inclusion criteria included recent injection drug use (previous 6 months) and HCV G1\/4 infection. Exclusion criteria included prior HCV treatment and decompensated liver disease. Participants received elbasvir\/grazoprevir once\u2010daily for 12\u2009weeks. The primary endpoint was undetectable HCV RNA 12\u2009weeks post\u2010treatment (SVR). Fingerstick whole\u2010blood samples were tested using the Xpert HCV Viral Load Fingerstick (Xpert HCV VL Fingerstick) assay and compared to the Aptima HCV Quant Dx Assay on plasma samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of a planned 150 participants, 32 were enrolled due to slower than anticipated recruitment [median age 46\u2009years, 10 (31%) female, 29 (91%) G1a]. Eighteen (56%) were receiving opioid agonist therapy and 29 (91%) injected in the previous month. Twenty\u2010six (81%) of 32 completed treatment (lost to follow\u2010up, n = 5; incarceration, n = 1). There were no virological failures. Twenty\u2010four (75%, 95% CI 59%\u201091%) of 32 achieved SVR. Two participants who completed treatment did not have SVR (loss to follow\u2010up, n = 1; refused test, n = 1). Among paired samples (n = 36), sensitivity of the Xpert HCV VL Fingerstick assay for HCV RNA detection was 100.0% (95% CI 75.3%\u2010100.0%) and specificity was 95.7% (95% CI 78.1%\u201099.9%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Elbasvir\/grazoprevir is effective among people with HCV G1 with recent injecting drug use. Implementation of point\u2010of\u2010care HCV RNA testing was feasible, but the high error rate requires investigation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hsr2.151","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T06:34:15Z","timestamp":1584340455000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO\u2010C): An open\u2010label, single\u2010arm, phase 4, multicentre trial"],"prefix":"10.1002","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-2017","authenticated-orcid":false,"given":"Jason","family":"Grebely","sequence":"first","affiliation":[{"name":"Viral Hepatitis Clinical Research Program The Kirby Institute, UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-3777","authenticated-orcid":false,"given":"Phillip","family":"Read","sequence":"additional","affiliation":[{"name":"Kirketon Road Centre  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-3473","authenticated-orcid":false,"given":"Evan B.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program The Kirby Institute, UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weltman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Nepean Hospital  Penrith Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program The Kirby Institute, UNSW Sydney  Sydney Australia"},{"name":"Department of Infectious Diseases St Vincent's Hospital  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Newcastle Pharmacotherapy Service  Newcastle Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Montebello","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services South East Sydney Local Health District  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-0186","authenticated-orcid":false,"given":"Marianne","family":"Martinello","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program The Kirby Institute, UNSW Sydney  Sydney Australia"},{"name":"Department of Infectious Diseases St Vincent's Hospital  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Gilliver","sequence":"additional","affiliation":[{"name":"Kirketon Road Centre  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Marks","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program The Kirby Institute, UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8657-4261","authenticated-orcid":false,"given":"Tanya L.","family":"Applegate","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program The Kirby Institute, UNSW Sydney  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-2622","authenticated-orcid":false,"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Clinical Research Program The Kirby Institute, UNSW Sydney  Sydney Australia"},{"name":"Department of Infectious Diseases St Vincent's Hospital  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the DARLO\u2010C Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30375-3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14393"},{"key":"e_1_2_10_5_1","volume-title":"Global Hepatitis Report 2017","author":"WHO","year":"2017"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30304-2"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0816"},{"key":"e_1_2_10_8_1","first-page":"431a","article-title":"HCV reinfection and injecting risk behavior following elbasvir\/grazoprevir treatment in patients on opioid agonist therapy: co\u2010STAR three year follow\u2010up study","volume":"64","author":"Dore G","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120701426524"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12869"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.08.011"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207226"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03749.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-645"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230801956116"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30075-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy114"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2017.1400385"},{"key":"e_1_2_10_19_1","volume-title":"Australian Recommendations for the Management of Hepatitis C Virus Infection: A Consensus Statement","author":"Gastroenterological Society of Australia. Hepatitis C Virus Infection Consensus Statement Working Group","year":"2018"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30404-1"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.10.004"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.020"},{"key":"e_1_2_10_23_1","volume-title":"WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy","author":"WHO","year":"2010"},{"key":"e_1_2_10_24_1","unstructured":"Cepheid. Xpert\u00ae HCV VL Fingerstick; 2019."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.16.1789"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.018"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01958.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13175"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.05.003"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.033"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.05.040"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.05.011"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz633"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2019.06.007"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa037"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhsr2.151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T08:14:08Z","timestamp":1693988048000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,15]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/hsr2.151"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.151","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,15]]},"assertion":[{"value":"2019-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e151"}}